These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22391131)

  • 1. High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation.
    Tzenaki N; Andreou M; Stratigi K; Vergetaki A; Makrigiannakis A; Vanhaesebroeck B; Papakonstanti EA
    FASEB J; 2012 Jun; 26(6):2498-508. PubMed ID: 22391131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages.
    Goulielmaki E; Bermudez-Brito M; Andreou M; Tzenaki N; Tzardi M; de Bree E; Tsentelierou E; Makrigiannakis A; Papakonstanti EA
    Cell Death Dis; 2018 Jun; 9(6):678. PubMed ID: 29880805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.
    Papakonstanti EA; Zwaenepoel O; Bilancio A; Burns E; Nock GE; Houseman B; Shokat K; Ridley AJ; Vanhaesebroeck B
    J Cell Sci; 2008 Dec; 121(Pt 24):4124-33. PubMed ID: 19033389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
    Berenjeno IM; Guillermet-Guibert J; Pearce W; Gray A; Fleming S; Vanhaesebroeck B
    Biochem J; 2012 Feb; 442(1):151-9. PubMed ID: 22150431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focal adhesion kinase phosphorylates the phosphatase and tensin homolog deleted on chromosome 10 under the control of p110δ phosphoinositide-3 kinase.
    Tzenaki N; Aivaliotis M; Papakonstanti EA
    FASEB J; 2015 Dec; 29(12):4840-52. PubMed ID: 26251180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.
    Jiang X; Chen S; Asara JM; Balk SP
    J Biol Chem; 2010 May; 285(20):14980-14989. PubMed ID: 20231295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
    Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
    Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
    [No Abstract]   [Full Text] [Related]  

  • 8. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
    Edgar KA; Wallin JJ; Berry M; Lee LB; Prior WW; Sampath D; Friedman LS; Belvin M
    Cancer Res; 2010 Feb; 70(3):1164-72. PubMed ID: 20103642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
    Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of deleting p110delta on the phenotype and function of PTEN-deficient B cells.
    Janas ML; Hodson D; Stamataki Z; Hill S; Welch K; Gambardella L; Trotman LC; Pandolfi PP; Vigorito E; Turner M
    J Immunol; 2008 Jan; 180(2):739-46. PubMed ID: 18178811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
    Zhang C; Xu B; Liu P
    Tumour Biol; 2016 Nov; 37(11):14831-14839. PubMed ID: 27639383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imbalanced PTEN and PI3K Signaling Impairs Class Switch Recombination.
    Chen Z; Getahun A; Chen X; Dollin Y; Cambier JC; Wang JH
    J Immunol; 2015 Dec; 195(11):5461-5471. PubMed ID: 26500350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
    Aragoneses-Fenoll L; Montes-Casado M; Ojeda G; Acosta YY; Herranz J; Martínez S; Blanco-Aparicio C; Criado G; Pastor J; Dianzani U; Portolés P; Rojo JM
    Biochem Pharmacol; 2016 Apr; 106():56-69. PubMed ID: 26883061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTEN-deficient cancers depend on PIK3CB.
    Wee S; Wiederschain D; Maira SM; Loo A; Miller C; deBeaumont R; Stegmeier F; Yao YM; Lengauer C
    Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13057-62. PubMed ID: 18755892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner.
    Sun J; Mohlin S; Lundby A; Kazi JU; Hellman U; Påhlman S; Olsen JV; Rönnstrand L
    Oncogene; 2014 Nov; 33(46):5360-9. PubMed ID: 24213578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells.
    Ma J; Sawai H; Matsuo Y; Ochi N; Yasuda A; Takahashi H; Wakasugi T; Funahashi H; Sato M; Takeyama H
    J Surg Res; 2010 May; 160(1):90-101. PubMed ID: 19560785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
    Fang J; Ding M; Yang L; Liu LZ; Jiang BH
    Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta.
    Sawyer C; Sturge J; Bennett DC; O'Hare MJ; Allen WE; Bain J; Jones GE; Vanhaesebroeck B
    Cancer Res; 2003 Apr; 63(7):1667-75. PubMed ID: 12670921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p110δ PI3 kinase pathway: emerging roles in cancer.
    Tzenaki N; Papakonstanti EA
    Front Oncol; 2013; 3():40. PubMed ID: 23459844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.